Loading institutional data...
Loading institutional data...
Held by 247 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -22%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $93M covers all $46M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2015-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M 100.0% | $233.2M 100.0% | $145.2M 100.0% | $109.5M 100.0% | $131.8M 100.0% | $198.3M 100.0% | $175.3M 100.0% | $164.2M 100.0% | $154.9M 100.0% | $133.6M 100.0% |
| Cost of Revenue | $10.3M 2.1% | $7.7M 3.3% | $11.4M 7.9% | $4.4M 4.0% | $3.8M 2.9% | $6.1M 3.1% | $5.2M 3.0% | $5.5M 3.4% | $3.6M 2.3% | $4.6M 3.4% |
| Cost of Products | — | — | — | — | — | — | — | — | $3.6M 2.3% | $4.6M 3.4% |
| Research & Development | — | — | — | $7.5M 6.9% | — | — | $141.0M 80.4% | $123.8M 75.3% | $78.2M 50.5% | $70.8M 53.0% |
| Selling, General & Admin | $337.2M 68.7% | $264.1M 113.3% | $265.5M 182.8% | $197.5M 180.4% | $126.3M 95.8% | $135.8M 68.5% | $129.0M 73.5% | $103.7M 63.1% | $101.3M 65.4% | $91.9M 68.8% |
| Total Operating Expenses | $553.6M 112.8% | $557.0M 238.9% | $533.4M 367.2% | $429.3M 392.2% | $331.3M 251.3% | $374.5M 188.8% | $312.7M 178.3% | $244.3M 148.7% | $208.7M 134.7% | $191.8M 143.6% |
| Operating Income | -$62.8M -12.8% | -$323.8M -138.9% | -$388.1M -267.2% | -$319.8M -292.2% | -$199.4M -151.3% | -$176.2M -88.8% | -$137.4M -78.3% | -$80.0M -48.7% | -$53.8M -34.7% | -$58.2M -43.6% |
| Interest Expense | $10.7M 2.2% | $11.2M 4.8% | $11.3M 7.8% | $11.0M 10.0% | $19.7M 14.9% | $19.1M 9.6% | $18.8M 10.7% | $9.8M 6.0% | $4.4M 2.9% | $4.7M 3.5% |
| Interest & Investment Income | $12.7M 2.6% | $17.8M 7.6% | $21.8M 15.0% | $6.3M 5.7% | $2.0M 1.5% | $5.0M 2.5% | $10.1M 5.7% | $5.5M 3.3% | $3.2M 2.1% | — |
| Other Income (Expense), net | $13.6M 2.8% | $3.3M 1.4% | $12.0M 8.3% | -$11.3M -10.4% | -$17.5M -13.2% | -$12.6M -6.4% | -$9.1M -5.2% | -$21.8M -13.3% | -$4.6M -3.0% | $632K 0.5% |
| Pretax Income | -$49.3M -10.0% | -$320.5M -137.5% | -$376.1M -259.0% | -$331.2M -302.5% | -$216.9M -164.5% | -$188.8M -95.2% | -$146.4M -83.5% | -$101.9M -62.0% | -$58.4M -37.7% | -$57.6M -43.1% |
| Income Tax Expense | $988K 0.2% | $120K 0.1% | $223K 0.2% | $313K 0.3% | $409K 0.3% | -$19.4M -9.8% | -$21K -0.0% | $811K 0.5% | $1.4M 0.9% | -$9.7M -7.2% |
| Net Income | -$25.5M -5.2% | -$321.5M -137.9% | -$111.4M -76.7% | -$278.5M -254.4% | -$180.1M -136.6% | -$169.4M -85.4% | -$146.4M -83.5% | -$102.7M -62.5% | -$59.7M -38.6% | -$47.9M -35.9% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 | $-1.54 | $-1.29 |
| EPS (Diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 | $-1.54 | $-1.29 |
| Weighted Avg Shares (Basic) | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M | 42.3M | 40.4M | 38.8M | 37.0M |
| Weighted Avg Shares (Diluted) | 89.2M | 78.9M | 74.3M | 63.8M | 59.8M | 47.5M | 42.3M | 40.4M | 38.8M | 38.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 92th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 3.4 | 3.0 | 3.1 | 2.9 | 4.0 | 7.9 | 3.3 | 2.1 |
| R&D | 75.3 | 80.4 | — | — | 6.9 | — | — | — |
| SG&A | 63.1 | 73.5 | 68.5 | 95.8 | 180.4 | 182.8 | 113.3 | 68.7 |
| Operating Income | -48.7 | -78.3 | -88.8 | -151.3 | -292.2 | -267.2 | -138.9 | -12.8 |
| Income Tax | 0.5 | -0.0 | -9.8 | 0.3 | 0.3 | 0.2 | 0.1 | 0.2 |
| Net Income | -62.5 | -83.5 | -85.4 | -136.6 | -254.4 | -76.7 | -137.9 | -5.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TVTX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| TVTX | $5.9B | — | — | 12.0× | 110% | 97.9% | -5.2% | -22.2% | -22.2% | — | 247 |
Peers = companies sharing TVTX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.